QUEST Clinical Trial Summary


The QUEST study is for men with metastatic prostate cancer (which means that cancer has spread to other parts of the body such as bones, liver or lung), who have already received androgen receptor (AR)-targeted therapy, but the cancer has still progressed.

WHY IS THIS CLINICAL RESEARCH STUDY BEING DONE?  The objective of the study is to look at different combinations of an investigational drug in combination with other investigational anticancer drugs, to see whether they are safe and effective (how well something works) for the treatment of prostate cancer. 

WHAT TREATMENT WILL I RECEIVE? If you are eligible, you will receive the investigational medication in combination with another investigational anticancer drug. The combination assigned to you will depend on the eligibility criteria you meet, your prior treatments and the characteristics of your tumor. 

If you are enrolled into the study, you will receive the combination of the two investigational drugs assigned to you for as long as you are benefiting from these medicines and are not having any serious side effects, as determined by the study doctor.

The QUEST study is an open-label study, which means you and the study doctor will know the investigational drugs you are receiving.

AM I ELIGIBLE?  You may be eligible to participate in this study if you: 


  • Are a male, age 18 or older
  • Have a diagnosis of metastatic prostate cancer (which means that cancer has spread to other parts in your body such as bones, liver or lung)
  • Are willing to provide a blood sample and tumor tissue sample as part of the study
  • Have had prior treatment with a novel androgen receptor (AR)-targeted therapy (for example Xtandi® (enzalutamide) or Zytiga® (abiraterone) to treat your prostate cancer 

Before you participate in this study, a detailed description of the study, as well as possible risks and benefits, will be provided in writing in an “informed consent document” which will be discussed with you. You will be asked to review and sign the informed consent document prior to participating. Your medical history will be reviewed, and you will be given a study-required medical exam and have study-required laboratory tests such as blood draws. 

Organization: Janssen


To learn more about this study and to find out if you may be eligible and if the study is being conducted at a site near you, please visit:



Register your interest or comments about this trial with PHEN


PHEN Contact: 617-481-4020 option 3 for Dr. Keith Crawford 
or his direct dial number is 617-302-3987.


Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.

Go Back



PHEN,Inc. © 2020 All rights reserved